Valuation
- Market cap
- 35,856,000
- Revenue TTM
- $38,730,000
- Net income TTM
- $24,580,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 63.47%
- Debt to equity
- 0.00
Trading
- Volume
- 1,400
- Avg volume
- 2,179
- Day's range
- $6.45 – $6.55
- Shares out
- 5,542,000
- Stochastic %K
- 60%
- Beta
- 0.61
- Analysts
- —
- Price target
- —
Company profile
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, c...
Show more
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- Phone
- 855 776 6419
- Website
- https://www.interpace.com
- Address
- Waterview Plaza, Suite 310 2001 Route 46, Parsippany, United States
Latest news
No headlines yet.
